Tag: Nasdaq:GLSI

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:GLSI

FPT Corporation Strengthens Vietnam-Korea Partnerships in Semiconductors and High-Quality Workforce Training

Chisholm Chisholm & Kilpatrick LTD and National Veterans Legal Services Program Challenge VA’s Denial of Benefits to Caregivers after Veterans’ Deaths

KLC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against KinderCare Learning Companies, Inc. and Announces Opportunity for Investors with...

Tag: Nasdaq:GLSI

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us